Dupixent Pediatric Side Effects: What Parents Need to Know

Medically reviewed by licensed healthcare professionals · Legally reviewed by mass tort litigation specialists · Last updated: March 2026

Dupixent (dupilumab) has been a significant treatment advance for children with moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and certain types of asthma. While generally considered safe and effective, it's important for parents to understand the side effect profile in children, which can differ slightly from adults.

Safety Data in Pediatric Patients

The FDA approval of Dupixent for pediatric populations was based on clinical trials specifically conducted in children and adolescents. For atopic dermatitis, trials have included patients from 6 months to 17 years old. These studies found that the overall safety profile of Dupixent in children was comparable to that in adults.

Common Side Effects in Children

The most common adverse reactions reported in pediatric Dupixent trials are similar to those in adults:

• Injection site reactions: Redness, swelling, and pain at the injection site are common but usually mild and transient.
• Conjunctivitis (pink eye): Eye and eyelid inflammation is one of the most frequently reported side effects. In some pediatric studies, the incidence of conjunctivitis was slightly higher than in adult trials.
• Oral herpes: Cold sore outbreaks were reported more frequently in the Dupixent group than the placebo group in some trials.
• Eosinophilia: An increase in the number of eosinophils in the blood is a known effect. While often asymptomatic, doctors will monitor this with blood tests.
• Nasopharyngitis: Symptoms of the common cold.

Specific Considerations for Younger Children (6 months to 5 years)

A study focusing on the youngest patient group (6 months to 5 years) with atopic dermatitis found a similar safety profile. However, some infections were reported more commonly in this age group, including hand-foot-and-mouth disease and skin papilloma (common warts). This is likely because young children in general have higher rates of these common viral illnesses, but parents should be aware of these findings.

Long-Term Safety and the Developing Immune System

One of the key unanswered questions for any long-term immune-modulating drug in children is its effect on the developing immune system. The immune system undergoes critical maturation throughout childhood and adolescence. The long-term impact of blocking the IL-4/IL-13 pathway during these developmental windows is not yet fully known.

Current data from multi-year extension studies is reassuring and has not revealed any significant long-term safety concerns related to immune function, such as an increased risk of serious infections or malignancies. However, this remains an area of ongoing monitoring and research.

What Parents Should Watch For

Parents should work closely with their child's pediatrician and specialist (dermatologist, allergist, or pulmonologist) and report any new or worsening symptoms, particularly:

• Any eye redness, itching, or discharge (see an ophthalmologist if this occurs).
• New or unusual rashes.
• Any signs of a serious infection.
• Any new joint pain or swelling.